Pharmacogenetics: implications for therapy in rheumatic diseases
- 9 August 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 7 (9), 537-550
- https://doi.org/10.1038/nrrheum.2011.117
Abstract
DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.Keywords
This publication has 114 references indexed in Scilit:
- Metaanalysis of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms Affecting Methotrexate ToxicityThe Journal of Rheumatology, 2009
- STAT4and the Risk of Rheumatoid Arthritis and Systemic Lupus ErythematosusThe New England Journal of Medicine, 2007
- A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritisArthritis & Rheumatism, 2007
- Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Relationship of glutathione S‐transferase genotypes with side‐effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosusBritish Journal of Clinical Pharmacology, 2006
- Regulatory Functions of 3′UTRsBiochemical and Biophysical Research Communications, 2001
- Assessing the cost-effectiveness of pharmacogenomicsAAPS PharmSci, 2000
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987
- Variables Affecting Efficacy and Toxicity of Sulphasalazine1 in Rheumatoid ArthritisDrugs, 1986
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisThe New England Journal of Medicine, 1985